JASPER THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $4.87M.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $5.94M.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was -$5.94M, a 112.59% decline year-over-year.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $4.87M.
- JASPER THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $96.97M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.87M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.87M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $5.94M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$5.94M derived: 10-K 12 month − 3 quarters · filed 2026-03-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $47.20M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $47.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | $47.20M 10-Q · filed 2024-05-14 | $47.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $96.97M 10-K · filed 2025-02-28 |
| 2023-09-30 | $40.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2023-03-31 | $96.93M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |